(51 days)
Not Found
Not Found
No
The device description outlines a chemical test kit and does not mention any computational analysis or algorithms beyond calculating a ratio.
No.
The device is used for diagnosis, not for treating a condition.
Yes
The device is described as "intended to measure the ratio of lactulose to mannitol in urine; the measurement is used in the diagnosis of gastrointestinal malabsorption syndrome," directly linking it to the diagnosis of a medical condition.
No
The device description clearly states it is a kit consisting of physical components like tubes, a pipette, collection cups, a biohazard bag, and a drink accessory. These are hardware components, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the measurement of the lactulose to mannitol ratio in urine is "used in the diagnosis of gastrointestinal malabsorption syndrome." This clearly indicates a diagnostic purpose.
- Device Description: The device is a kit designed to collect and prepare a biological specimen (urine) for analysis. The analysis itself (measuring lactulose and mannitol levels and calculating a ratio) is performed on this in vitro sample.
- Predicate Device: The predicate device listed is a "Xylose Test System," which is also an IVD used for assessing intestinal absorption. This further supports the classification of this device as an IVD.
IVDs are defined as reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. This device fits this definition by providing information derived from an in vitro sample (urine) that is used in the diagnosis of a specific medical condition (gastrointestinal malabsorption syndrome).
N/A
Intended Use / Indications for Use
The Great Smokies lactulose/mannitol test for intestinal permeability is intended to measure the ratio of lactulose to mannitol in urine; the measurement is used in the diagnosis of gastrointestinal malabsorption syndrome.
Product codes
JOC
Device Description
The device is a kit consisting of exempt components and accessories (urine specimen transport tubes (one white-capped "before drink" specimen tube and one purple-capped "after drink" specimen tube), a pipette, a small urine collection cup, a large urine collection container, a biohazard bag with absorbent pad, and a drink accessory (5g lactulose, 1g mannitol, 10g glycerine, and 3.84 ml water)). The drink is ingested after an overnight fast, and voided urine is then collected over a period of 6 hours to measure the level of lactulose and level of mannitol in urine and to obtain a ratio; the result is expressed as the percent recovery of an ingested dose of lactulose divided by the percent recovery of an ingested dose of mannitol. The measurement is used in the diagnosis of gastrointestinal malabsorption syndrome (a group of disorders in which there is abnormal absorption of dietary constituents, e.g., excessive absorption of substances or excessive loss from the body of nonabsorbed substances).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1820 Xylose test system.
(a)
Identification. A xylose test system is a device intended to measure xylose (a sugar) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of gastrointestinal malabsorption syndrome (a group of disorders in which there is subnormal absorption of dietary constituents and thus excessive loss from the body of the nonabsorbed substances).(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
991156
MAY 28 1999
| H. | 510(k) Summary | Date prepared: March 30, 1999 |
|---|---|---|
| 1. | Submitter: | Great Smokies Diagnostic Laboratory |
| 63 Zillicoa Street | ||
| Asheville, NC 28801 | ||
| (800) 522-4762 | ||
| Contact: | Dr. Stephen Barrie | |
| 2. | Classification Name: | Xylose Test System (21 CFR 862.1820) |
| Common Usual Name: | Intestinal Permeability Test System; | |
| Lactulose/Mannitol Test | ||
| Proprietary Name: | Great Smokies Diagnostic Laboratory | |
| Intestinal Permeability Test System |
3. Statement of Equivalence
Great Smokies lactulose/mannitol intestinal permeability test is substantially equivalent to preamendments devices classified under 21 CFR 862.1820, Xylose Test System, Class I (exempt from 510(k) as of February 2, 1998). Great Smokies intestinal permeability test system has the same intended use and similar technology and performance characteristics. In addition, mannitol and xylose are essentially the same compound and lactulose is insignificantly different from xylose. Like lactulose/mannitol test systems, xylose test systems are used to measure xylose (a sugar) in urine. The measurement is used in the diagnosis of gastrointestinal malabsorption syndrome.
4. Device Description
The device is a kit consisting of exempt components and accessories (urine specimen transport tubes (one white-capped "before drink" specimen tube and one purple-capped "after drink" specimen tube), a pipette, a small urine collection cup, a large urine collection container, a biohazard bag with absorbent pad, and a drink accessory (5g lactulose, 1g mannitol, 10g glycerine, and 3.84 ml water)). The drink is ingested after an overnight fast, and voided urine is then collected over a period of 6 hours to measure the level of lactulose and level of mannitol in urine and to obtain a ratio; the result is expressed as the percent recovery of an ingested dose of lactulose divided by the percent recovery of an ingested dose of mannitol. The measurement is used in the diagnosis of gastrointestinal malabsorption syndrome (a group of disorders in which there is abnormal absorption of dietary constituents, e.g., excessive absorption of substances or excessive loss from the body of nonabsorbed substances).
1
5. Indications For Use
The Great Smokies lactulose/mannitol test for intestinal permeability is intended to measure the ratio of lactulose to mannitol in urine; the measurement is used in the diagnosis of gastrointestinal malabsorption syndrome.
6. Technological Characteristics
The technological characteristics of the device do not vary from those in the claimed predicate, except that mannitol is substituted for xylose and lactulose is added as an internal control.
2
Public Health Service
Image /page/2/Picture/2 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three lines representing its wings and head. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" is arranged in a circular fashion around the eagle image.
MAY 2 8 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Dr. Stephen Barrie Official Correspondent Great Smokies Diagnostic Laboratory 63 Zillicoa Street Asheville, NC 28801
Re: K991156 Trade Name: Great Smokies Diagnostic Laboratory Intestinal Permeability Test System Regulatory Class: I Product Code: JOC Dated: March 30, 1999 Received: April 07, 1999
Dear Dr. Barrie:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Putman
Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
B. Indications for Use
The Great Smokies lactulose/mannitol test for intestinal permeability is intended to measure the ratio of lactulose to mannitol in urine; the measurement is used in the diagnosis of gastrointestinal malabsorption syndrome.
Seán Cooper
(Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number_1991154
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use _V
OR
Over the Counter Use _________________________________________________________________________________________________________________________________________________________